Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda
The objective of this study was to determine the prevalence and some predictors for vaccine and non-vaccine types of HPV infections among bivalent HPV vaccinated and non-vaccinated young women in Uganda. This was a comparative cross sectional study 5.5 years after a bivalent HPV 16/18 vaccination (C...
Uloženo v:
| Vydáno v: | PloS one Ročník 11; číslo 8; s. e0160099 |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Public Library of Science
02.08.2016
Public Library of Science (PLoS) |
| Témata: | |
| ISSN: | 1932-6203, 1932-6203 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The objective of this study was to determine the prevalence and some predictors for vaccine and non-vaccine types of HPV infections among bivalent HPV vaccinated and non-vaccinated young women in Uganda. This was a comparative cross sectional study 5.5 years after a bivalent HPV 16/18 vaccination (Cervarix®, GlaxoSmithKline, Belgium) pilot project in western Uganda. Cervical swabs were collected between July 2014-August 2014 and analyzed with a HPV genotyping test, CLART® HPV2 assay (Genomica, Madrid Spain) which is based on PCR followed by microarray for determination of genotype. Blood samples were also tested for HIV and syphilis infections as well as CD4 and CD8 lymphocyte levels. The age range of the participants was 15-24 years and mean age was 18.6(SD 1.4). Vaccine-type HPV-16/18 strains were significantly less prevalent among vaccinated women compared to non-vaccinated women (0.5% vs 5.6%, p 0.006, OR 95% CI 0.08(0.01-0.64). At type-specific level, significant difference was observed for HPV16 only. Other STIs (HIV/syphilis) were important risk factors for HPV infections including both vaccine types and non-vaccine types. In addition, for non-vaccine HPV types, living in an urban area, having a low BMI, low CD4 count and having had a high number of life time sexual partners were also significant risk factors. Our data concurs with the existing literature from other parts of the world regarding the effectiveness of bivalent HPV-16/18 vaccine in reducing the prevalence of HPV infections particularly vaccine HPV- 16/18 strains among vaccinated women. This study reinforces the recommendation to vaccinate young girls before sexual debut and integrate other STI particularly HIV and syphilis interventions into HPV vaccination packages. |
|---|---|
| AbstractList | The objective of this study was to determine the prevalence and some predictors for vaccine and non-vaccine types of HPV infections among bivalent HPV vaccinated and non-vaccinated young women in Uganda. This was a comparative cross sectional study 5.5 years after a bivalent HPV 16/18 vaccination (Cervarix®, GlaxoSmithKline, Belgium) pilot project in western Uganda. Cervical swabs were collected between July 2014-August 2014 and analyzed with a HPV genotyping test, CLART® HPV2 assay (Genomica, Madrid Spain) which is based on PCR followed by microarray for determination of genotype. Blood samples were also tested for HIV and syphilis infections as well as CD4 and CD8 lymphocyte levels. The age range of the participants was 15-24 years and mean age was 18.6(SD 1.4). Vaccine-type HPV-16/18 strains were significantly less prevalent among vaccinated women compared to non-vaccinated women (0.5% vs 5.6%, p 0.006, OR 95% CI 0.08(0.01-0.64). At type-specific level, significant difference was observed for HPV16 only. Other STIs (HIV/syphilis) were important risk factors for HPV infections including both vaccine types and non-vaccine types. In addition, for non-vaccine HPV types, living in an urban area, having a low BMI, low CD4 count and having had a high number of life time sexual partners were also significant risk factors. Our data concurs with the existing literature from other parts of the world regarding the effectiveness of bivalent HPV-16/18 vaccine in reducing the prevalence of HPV infections particularly vaccine HPV- 16/18 strains among vaccinated women. This study reinforces the recommendation to vaccinate young girls before sexual debut and integrate other STI particularly HIV and syphilis interventions into HPV vaccination packages. The objective of this study was to determine the prevalence and some predictors for vaccine and non-vaccine types of HPV infections among bivalent HPV vaccinated and non-vaccinated young women in Uganda. This was a comparative cross sectional study 5.5 years after a bivalent HPV 16/18 vaccination (Cervarix®, GlaxoSmithKline, Belgium) pilot project in western Uganda. Cervical swabs were collected between July 2014-August 2014 and analyzed with a HPV genotyping test, CLART® HPV2 assay (Genomica, Madrid Spain) which is based on PCR followed by microarray for determination of genotype. Blood samples were also tested for HIV and syphilis infections as well as CD4 and CD8 lymphocyte levels. The age range of the participants was 15-24 years and mean age was 18.6(SD 1.4). Vaccine-type HPV-16/18 strains were significantly less prevalent among vaccinated women compared to non-vaccinated women (0.5% vs 5.6%, p 0.006, OR 95% CI 0.08(0.01-0.64). At type-specific level, significant difference was observed for HPV16 only. Other STIs (HIV/syphilis) were important risk factors for HPV infections including both vaccine types and non-vaccine types. In addition, for non-vaccine HPV types, living in an urban area, having a low BMI, low CD4 count and having had a high number of life time sexual partners were also significant risk factors. Our data concurs with the existing literature from other parts of the world regarding the effectiveness of bivalent HPV-16/18 vaccine in reducing the prevalence of HPV infections particularly vaccine HPV- 16/18 strains among vaccinated women. This study reinforces the recommendation to vaccinate young girls before sexual debut and integrate other STI particularly HIV and syphilis interventions into HPV vaccination packages.The objective of this study was to determine the prevalence and some predictors for vaccine and non-vaccine types of HPV infections among bivalent HPV vaccinated and non-vaccinated young women in Uganda. This was a comparative cross sectional study 5.5 years after a bivalent HPV 16/18 vaccination (Cervarix®, GlaxoSmithKline, Belgium) pilot project in western Uganda. Cervical swabs were collected between July 2014-August 2014 and analyzed with a HPV genotyping test, CLART® HPV2 assay (Genomica, Madrid Spain) which is based on PCR followed by microarray for determination of genotype. Blood samples were also tested for HIV and syphilis infections as well as CD4 and CD8 lymphocyte levels. The age range of the participants was 15-24 years and mean age was 18.6(SD 1.4). Vaccine-type HPV-16/18 strains were significantly less prevalent among vaccinated women compared to non-vaccinated women (0.5% vs 5.6%, p 0.006, OR 95% CI 0.08(0.01-0.64). At type-specific level, significant difference was observed for HPV16 only. Other STIs (HIV/syphilis) were important risk factors for HPV infections including both vaccine types and non-vaccine types. In addition, for non-vaccine HPV types, living in an urban area, having a low BMI, low CD4 count and having had a high number of life time sexual partners were also significant risk factors. Our data concurs with the existing literature from other parts of the world regarding the effectiveness of bivalent HPV-16/18 vaccine in reducing the prevalence of HPV infections particularly vaccine HPV- 16/18 strains among vaccinated women. This study reinforces the recommendation to vaccinate young girls before sexual debut and integrate other STI particularly HIV and syphilis interventions into HPV vaccination packages. The objective of this study was to determine the prevalence and some predictors for vaccine and non-vaccine types of HPV infections among bivalent HPV vaccinated and non-vaccinated young women in Uganda. This was a comparative cross sectional study 5.5 years after a bivalent HPV 16/18 vaccination (Cervarix registered , GlaxoSmithKline, Belgium) pilot project in western Uganda. Cervical swabs were collected between July 2014-August 2014 and analyzed with a HPV genotyping test, CLART registered HPV2 assay (Genomica, Madrid Spain) which is based on PCR followed by microarray for determination of genotype. Blood samples were also tested for HIV and syphilis infections as well as CD4 and CD8 lymphocyte levels. The age range of the participants was 15-24 years and mean age was 18.6(SD 1.4). Vaccine-type HPV-16/18 strains were significantly less prevalent among vaccinated women compared to non-vaccinated women (0.5% vs 5.6%, p 0.006, OR 95% CI 0.08(0.01-0.64). At type-specific level, significant difference was observed for HPV16 only. Other STIs (HIV/syphilis) were important risk factors for HPV infections including both vaccine types and non-vaccine types. In addition, for non-vaccine HPV types, living in an urban area, having a low BMI, low CD4 count and having had a high number of life time sexual partners were also significant risk factors. Our data concurs with the existing literature from other parts of the world regarding the effectiveness of bivalent HPV-16/18 vaccine in reducing the prevalence of HPV infections particularly vaccine HPV- 16/18 strains among vaccinated women. This study reinforces the recommendation to vaccinate young girls before sexual debut and integrate other STI particularly HIV and syphilis interventions into HPV vaccination packages. The objective of this study was to determine the prevalence and some predictors for vaccine and non-vaccine types of HPV infections among bivalent HPV vaccinated and non-vaccinated young women in Uganda. This was a comparative cross sectional study 5.5 years after a bivalent HPV 16/18 vaccination (Cervarix®, GlaxoSmithKline, Belgium) pilot project in western Uganda. Cervical swabs were collected between July 2014-August 2014 and analyzed with a HPV genotyping test, CLART ® HPV2 assay (Genomica, Madrid Spain) which is based on PCR followed by microarray for determination of genotype. Blood samples were also tested for HIV and syphilis infections as well as CD4 and CD8 lymphocyte levels. The age range of the participants was 15–24 years and mean age was 18.6(SD 1.4). Vaccine-type HPV-16/18 strains were significantly less prevalent among vaccinated women compared to non-vaccinated women (0.5% vs 5.6%, p 0.006, OR 95% CI 0.08(0.01–0.64). At type-specific level, significant difference was observed for HPV16 only. Other STIs (HIV/syphilis) were important risk factors for HPV infections including both vaccine types and non-vaccine types. In addition, for non-vaccine HPV types, living in an urban area, having a low BMI, low CD4 count and having had a high number of life time sexual partners were also significant risk factors. Our data concurs with the existing literature from other parts of the world regarding the effectiveness of bivalent HPV-16/18 vaccine in reducing the prevalence of HPV infections particularly vaccine HPV- 16/18 strains among vaccinated women. This study reinforces the recommendation to vaccinate young girls before sexual debut and integrate other STI particularly HIV and syphilis interventions into HPV vaccination packages. The objective of this study was to determine the prevalence and some predictors for vaccine and non-vaccine types of HPV infections among bivalent HPV vaccinated and non-vaccinated young women in Uganda. This was a comparative cross sectional study 5.5 years after a bivalent HPV 16/18 vaccination (Cervarix®, GlaxoSmithKline, Belgium) pilot project in western Uganda. Cervical swabs were collected between July 2014-August 2014 and analyzed with a HPV genotyping test, CLART.sup.® HPV2 assay (Genomica, Madrid Spain) which is based on PCR followed by microarray for determination of genotype. Blood samples were also tested for HIV and syphilis infections as well as CD4 and CD8 lymphocyte levels. The age range of the participants was 15-24 years and mean age was 18.6(SD 1.4). Vaccine-type HPV-16/18 strains were significantly less prevalent among vaccinated women compared to non-vaccinated women (0.5% vs 5.6%, p 0.006, OR 95% CI 0.08(0.01-0.64). At type-specific level, significant difference was observed for HPV16 only. Other STIs (HIV/syphilis) were important risk factors for HPV infections including both vaccine types and non-vaccine types. In addition, for non-vaccine HPV types, living in an urban area, having a low BMI, low CD4 count and having had a high number of life time sexual partners were also significant risk factors. Our data concurs with the existing literature from other parts of the world regarding the effectiveness of bivalent HPV-16/18 vaccine in reducing the prevalence of HPV infections particularly vaccine HPV- 16/18 strains among vaccinated women. This study reinforces the recommendation to vaccinate young girls before sexual debut and integrate other STI particularly HIV and syphilis interventions into HPV vaccination packages. |
| Audience | Academic |
| Author | Kumakech, Edward Musubika, Caroline Kirimunda, Samuel Helenius, Gisela Kaliff, Malin Karlsson, Mats Andersson, Sören Lillsunde-Larsson, Gabriella Wabinga, Henry Berggren, Vanja |
| AuthorAffiliation | 3 Faculty of Medicine, Lund University, Lund, Sweden Rudjer Boskovic Institute, CROATIA 5 Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University Hospital and Örebro University, Örebro, Sweden 2 Department of Pathology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda 1 School of Health and Medical Sciences, Örebro University, Örebro, Sweden 4 Department of Public Health (Global Health/IHCAR), Karolinska Institute, Stockholm, Sweden |
| AuthorAffiliation_xml | – name: 5 Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University Hospital and Örebro University, Örebro, Sweden – name: Rudjer Boskovic Institute, CROATIA – name: 4 Department of Public Health (Global Health/IHCAR), Karolinska Institute, Stockholm, Sweden – name: 2 Department of Pathology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda – name: 3 Faculty of Medicine, Lund University, Lund, Sweden – name: 1 School of Health and Medical Sciences, Örebro University, Örebro, Sweden |
| Author_xml | – sequence: 1 givenname: Edward orcidid: 0000-0002-7237-7734 surname: Kumakech fullname: Kumakech, Edward – sequence: 2 givenname: Vanja surname: Berggren fullname: Berggren, Vanja – sequence: 3 givenname: Henry surname: Wabinga fullname: Wabinga, Henry – sequence: 4 givenname: Gabriella surname: Lillsunde-Larsson fullname: Lillsunde-Larsson, Gabriella – sequence: 5 givenname: Gisela surname: Helenius fullname: Helenius, Gisela – sequence: 6 givenname: Malin surname: Kaliff fullname: Kaliff, Malin – sequence: 7 givenname: Mats surname: Karlsson fullname: Karlsson, Mats – sequence: 8 givenname: Samuel surname: Kirimunda fullname: Kirimunda, Samuel – sequence: 9 givenname: Caroline surname: Musubika fullname: Musubika, Caroline – sequence: 10 givenname: Sören surname: Andersson fullname: Andersson, Sören |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27482705$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-51618$$DView record from Swedish Publication Index (Örebro universitet) http://kipublications.ki.se/Default.aspx?queryparsed=id:134072786$$DView record from Swedish Publication Index (Karolinska Institutet) |
| BookMark | eNqNlF1u1DAQxyNURD_gBggsIaFWYrd24iQ2D0ilQFupolW_UJ8sxxlvXbL24iSlvRSH4ApcCGc3RbtVi6o8xJr5zX8mM86sRkvWWYiilwQPSZKTzUvXeiur4SSYh5hkGHP-JFohPIkHWYyTpbnzcrRa15cYpwnLsmfRcpxTFuc4XYn-HJuRNdooaZvqBh1B2Soo0Q5YN_FwJSuwCpDT6EwqZSwMTm4mgHYPzwYk2yQM7VkNqjHO1kiOnR31nGyCyLYbT6QPh8ahr84O5lznrg3sNzcGi9Jhis5B-qCgG_BIoo9mmriZy9OnR-vb4K-kN9e_f22gQ1O5Bh16dxlqQMai05G0pXwePdWyquFF_16LTr98PtneHewf7Oxtb-0PFOO4GWiuZamZzFKpS1yUWAGWoGiegFSU0STWsdIFZzzTWudSF7SgNM4zFtykVMla9HqmO6lcLfp51IIwzBIaSBaIvRlROnkpJt6Mpb8RThoxNTg_EtI3RlUgilhRRRJZQE6ozFlRQIwzzXnKYiVTHrQGM636J0zaYkGtN30PJxApTihOAi8f5CfON7ISHurQd3UhqrYLDFQVLsJ0mkJyUiiOc8EJJ4KSNBMsi3OR6dA9wEnwdznePZjjkznbmn6h861ISUa6dnzoG9YWYyhVGLEPZSxUtuCx5kKM3JWgPMddV9ei9V7Aux8t1I0Ym1pBVUkLru1aTwhjGWWPQTHHNM0TEtA3d9D7Z9lTo3A3hbHahRJVJyq2aMrznPC8o4b3UOEpYWxU-FW1CfaFgI2FgMA0cN2MZFvXYu_46PHswdki-3aOvQBZNRe1q9rZdBfAV_ND-TeN2x0RgPczQHlX1x60UKaZ3pLwaaYSBItuId02TXQLSfQLKQTTO8G3-v8N-wsJdZJZ |
| CitedBy_id | crossref_primary_10_1186_s12879_025_10520_6 crossref_primary_10_1007_s10096_021_04393_1 crossref_primary_10_3390_ijerph15071447 crossref_primary_10_1016_j_vaccine_2017_07_113 crossref_primary_10_1093_infdis_jix582 crossref_primary_10_3390_diagnostics14040451 crossref_primary_10_3390_pathogens12081032 crossref_primary_10_1016_j_canep_2025_102759 |
| Cites_doi | 10.1186/1471-2334-8-85 10.1186/1750-9378-6-11 10.1002/ijc.21655 10.1016/S0140-6736(09)61248-4 10.1186/1750-9378-4-8 10.1016/j.virol.2013.07.015 10.1186/1471-2334-14-87 10.1186/1471-2334-11-13 10.1056/NEJMoa021641 10.1186/1750-9378-5-7 10.1086/526792 10.1002/jmv.21952 10.5858/2003-127-940-HPTM 10.1111/tmi.12549 10.1016/j.vaccine.2006.05.115 10.1097/00042560-199510050-00005 10.1186/1750-9378-6-8 10.1016/j.virol.2010.02.002 10.1016/j.vaccine.2014.06.038 10.1038/bjc.2014.198 10.1097/00042560-199808010-00011 10.1002/ijc.23762 10.1016/j.vaccine.2013.10.085 10.1097/IGC.0000000000000084 10.2471/BLT.11.089862 10.1002/ijc.27586 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10.1002/ijc.28661 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2016 Public Library of Science 2016 Kumakech et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2016 Kumakech et al 2016 Kumakech et al |
| Copyright_xml | – notice: COPYRIGHT 2016 Public Library of Science – notice: 2016 Kumakech et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2016 Kumakech et al 2016 Kumakech et al |
| CorporateAuthor | Department of Health Sciences Hälsa i ett tvärvetenskapligt perspektiv Faculty of Medicine Lunds universitet Institutionen för hälsovetenskaper Medicinska fakulteten Lund University Integrative Health Research |
| CorporateAuthor_xml | – name: Faculty of Medicine – name: Medicinska fakulteten – name: Institutionen för hälsovetenskaper – name: Lund University – name: Department of Health Sciences – name: Hälsa i ett tvärvetenskapligt perspektiv – name: Integrative Health Research – name: Lunds universitet |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM AABEP ADTPV AOWAS D8T D91 ZZAVC AGCHP D95 DOA |
| DOI | 10.1371/journal.pone.0160099 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Opposing Viewpoints Resource Center Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection Agricultural & Environmental Science Collection ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Technology collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Biological Science Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection Proquest Central Premium ProQuest One Academic ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) SWEPUB Örebro universitet full text SwePub SwePub Articles SWEPUB Freely available online SWEPUB Örebro universitet SwePub Articles full text SWEPUB Lunds universitet full text SWEPUB Lunds universitet DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Agricultural Science Database Genetics Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Genoprevalence of Vaccine-Type HPV |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1808344428 oai_doaj_org_article_b2c4c13abe714a78bbe206f99582ca59 oai_swepub_ki_se_503403 oai_portal_research_lu_se_publications_a91bc907_9191_4156_8627_6fc89e03a913 oai_DiVA_org_oru_51618 PMC4970808 4135752181 A459771978 27482705 10_1371_journal_pone_0160099 |
| Genre | Journal Article |
| GeographicLocations | Uganda Sweden Belgium United Kingdom--UK Africa England Kampala Uganda Germany |
| GeographicLocations_xml | – name: Uganda – name: England – name: Germany – name: United Kingdom--UK – name: Kampala Uganda – name: Sweden – name: Belgium – name: Africa |
| GrantInformation_xml | – fundername: ; grantid: Dnr: SWE-2010-146/348-2013-6172 |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACCTH ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFFHD AFKRA AFPKN AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAIFH BAWUL BBNVY BBTPI BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM 3V. ALIPV BBORY CGR CUY CVF ECM EIF IPNFZ NPM RIG 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO ESTFP FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 PUEGO 5PM AABEP ADTPV AOWAS D8T D91 ZZAVC AGCHP D95 - 02 AAPBV ABPTK ADACO B0M BBAFP KM |
| ID | FETCH-LOGICAL-c890t-f9fadf8a65afd0bd0ce0aec473eac48432f2cfb9896fff7afb4b442768ac41dc3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 8 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000381110700023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1932-6203 |
| IngestDate | Sun Jul 03 03:48:42 EDT 2022 Fri Oct 03 12:53:45 EDT 2025 Tue Nov 25 03:38:06 EST 2025 Tue Nov 04 16:04:05 EST 2025 Tue Nov 04 16:21:21 EST 2025 Tue Nov 04 01:53:23 EST 2025 Tue Oct 07 09:52:04 EDT 2025 Fri Sep 05 11:57:36 EDT 2025 Tue Oct 07 07:53:42 EDT 2025 Sat Nov 29 13:13:08 EST 2025 Sat Nov 29 10:25:36 EST 2025 Wed Nov 26 10:08:11 EST 2025 Wed Nov 26 09:31:38 EST 2025 Thu May 22 21:22:06 EDT 2025 Wed Feb 19 01:59:48 EST 2025 Sat Nov 29 03:39:56 EST 2025 Tue Nov 18 22:33:49 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c890t-f9fadf8a65afd0bd0ce0aec473eac48432f2cfb9896fff7afb4b442768ac41dc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: The authors have declared that no competing interests exist. Conceived and designed the experiments: EK VB SA HW GLL GH.Performed the experiments: EK GLL GH M. Kaliff M. Karlsson SK CM.Analyzed the data: EK SA GLL VB HW.Contributed reagents/materials/analysis tools: GLL GH M. Kaliff M. Karlsson SK CM HW.Wrote the paper: EK SA GLL VB SK CM HW. |
| ORCID | 0000-0002-7237-7734 |
| OpenAccessLink | https://doaj.org/article/b2c4c13abe714a78bbe206f99582ca59 |
| PMID | 27482705 |
| PQID | 1808344428 |
| PQPubID | 1436336 |
| ParticipantIDs | plos_journals_1808344428 doaj_primary_oai_doaj_org_article_b2c4c13abe714a78bbe206f99582ca59 swepub_primary_oai_swepub_ki_se_503403 swepub_primary_oai_portal_research_lu_se_publications_a91bc907_9191_4156_8627_6fc89e03a913 swepub_primary_oai_DiVA_org_oru_51618 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4970808 proquest_miscellaneous_1811886488 proquest_miscellaneous_1809045731 proquest_journals_1808344428 gale_infotracmisc_A459771978 gale_infotracacademiconefile_A459771978 gale_incontextgauss_ISR_A459771978 gale_incontextgauss_IOV_A459771978 gale_healthsolutions_A459771978 pubmed_primary_27482705 crossref_citationtrail_10_1371_journal_pone_0160099 crossref_primary_10_1371_journal_pone_0160099 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-08-02 |
| PublicationDateYYYYMMDD | 2016-08-02 |
| PublicationDate_xml | – month: 08 year: 2016 text: 2016-08-02 day: 02 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2016 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | A Chranioti (ref34) 2012; 34 N Muñoz (ref5) 2003; 348 J Paavonen (ref18) 2009; 374 D Johnson (ref29) 1995; 15 D Bzhalava (ref8) 2013; 445 A Luger (ref30) 1983; 95 ref1 B Lu (ref21) 2011; 11 A Pista (ref33) 2011; 83 (ref7) 2012 M Odida (ref14) 2011; 6 C Banura (ref12) 2011; 6 M Odida (ref11) 2008; 8 K Kavanagh (ref23) 2014; 110 J Palmroth (ref20) 2013; 131 C Banura (ref15) 2010; 5 Y Delerél (ref22) 2014; 14 M Schiffman (ref6) 2009; 4 DS LaMontagne (ref17) 2011; 89 E Moses (ref32) 2015; 20 C Banura (ref36) 2010; 5 C Banura (ref13) 2008; 197 HU Bernard (ref9) 2006; 118 A Hildesheim (ref19) 2014; 32 RG Downing (ref28) 1998; 18 D Mesher (ref24) 2014; 32 J Jeronimo (ref31) 2014; 24 N Munoz (ref4) 2006; 24S3 D. G. Altman (ref26) 1991 F. P. Polit (ref25) 2008 C Banura (ref16) 2008; 123 RA Hubbard (ref35) 2003; 127 JM Walboomers (ref3) 1999; 189 (ref27) 1995; 854 HR Wabinga (ref2) 2014; 135 HU Bernard (ref10) 2010; 401 24552260 - BMC Infect Dis. 2014 Feb 19;14:87 16949995 - Vaccine. 2006 Aug 31;24 Suppl 3:S3/1-10 12571259 - N Engl J Med. 2003 Feb 6;348(6):518-27 24736582 - Br J Cancer. 2014 May 27;110(11):2804-11 25018097 - Vaccine. 2014 Sep 3;32(39):5087-97 21749691 - Infect Agent Cancer. 2011 Jul 12;6(1):11 19486508 - Infect Agent Cancer. 2009 Jun 01;4:8 21702999 - Infect Agent Cancer. 2011 Jun 25;6(1):8 22084528 - Bull World Health Organ. 2011 Nov 1;89(11):821-830B 21181922 - J Med Virol. 2011 Feb;83(2):272-6 23301385 - Anal Quant Cytopathol Histpathol. 2012 Oct;34(5):257-63 20380709 - Infect Agent Cancer. 2010 Apr 09;5:7 26031572 - Trop Med Int Health. 2015 Oct;20(10):1355-67 8594834 - World Health Organ Tech Rep Ser. 1995;854:1-452 23928291 - Virology. 2013 Oct;445(1-2):224-31 19586656 - Lancet. 2009 Jul 25;374(9686):301-14 6356627 - Wien Klin Wochenschr. 1983 Jun 24;95(13):440-3 8548331 - J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15;10(5):522-30 24615279 - Int J Cancer. 2014 Jul 15;135(2):432-9 10451482 - J Pathol. 1999 Sep;189(1):12-9 21226933 - BMC Infect Dis. 2011 Jan 12;11:13 24557438 - Int J Gynecol Cancer. 2014 Mar;24(3):576-85 22492244 - Int J Cancer. 2012 Dec 15;131(12):2832-8 18237268 - J Infect Dis. 2008 Feb 15;197(4):555-62 20206957 - Virology. 2010 May 25;401(1):70-9 18711697 - Int J Cancer. 2008 Nov 1;123(9):2180-7 9704945 - J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 1;18(4):384-8 18577214 - BMC Infect Dis. 2008 Jun 24;8:85 12873165 - Arch Pathol Lab Med. 2003 Aug;127(8):940-5 24211166 - Vaccine. 2013 Dec 17;32(1):26-32 16331617 - Int J Cancer. 2006 Mar 1;118(5):1071-6 |
| References_xml | – volume: 8 start-page: 85 year: 2008 ident: ref11 article-title: Human Papillomavirus type distribution in invasive cervical cancer in Uganda publication-title: BMC Infect Dis doi: 10.1186/1471-2334-8-85 – volume: 6 start-page: 11 year: 2011 ident: ref12 article-title: Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review publication-title: Infect Agent Cancer doi: 10.1186/1750-9378-6-11 – volume: 118 start-page: 1071 issue: 5 year: 2006 ident: ref9 article-title: Genome variation of human papillomavirus types: phylogenetic and medical implications publication-title: Int J Cancer doi: 10.1002/ijc.21655 – ident: ref1 – volume: 374 start-page: 301 issue: 9686 year: 2009 ident: ref18 article-title: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women publication-title: Lancet doi: 10.1016/S0140-6736(09)61248-4 – volume: 4 start-page: 8 year: 2009 ident: ref6 article-title: Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline publication-title: Infect. Agent Cancer doi: 10.1186/1750-9378-4-8 – year: 2008 ident: ref25 – volume: 445 start-page: 224 year: 2013 ident: ref8 article-title: A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types publication-title: Virology doi: 10.1016/j.virol.2013.07.015 – volume: 854 start-page: 1 year: 1995 ident: ref27 article-title: Physical status: the use and interpretation of anthropometry: Report of a WHO Expert Committee publication-title: World Health Organ Tech Rep Ser – volume: 14 start-page: 87 year: 2014 ident: ref22 article-title: Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross sectional study via home-based self-sampling publication-title: BMC Infectious Diseases doi: 10.1186/1471-2334-14-87 – volume: 11 start-page: 13 year: 2011 ident: ref21 article-title: Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-Analysis publication-title: BMC Infectious Diseases doi: 10.1186/1471-2334-11-13 – volume: 348 start-page: 518 issue: 6 year: 2003 ident: ref5 article-title: International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa021641 – volume: 5 start-page: 7 year: 2010 ident: ref15 article-title: Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda publication-title: Infectious Agents and Cancer doi: 10.1186/1750-9378-5-7 – volume: 34 start-page: 257 issue: 5 year: 2012 ident: ref34 article-title: Comparison of two commercially available methods for HPV genotyping: CLART HPV2 and Linear Array HPV Genotyping tests publication-title: Anal Quant Cytopathol Histpathol – volume: 197 start-page: 555 issue: 4 year: 2008 ident: ref13 article-title: Infection with human papillomavirus and HIV among young women in Kampala, Uganda publication-title: J Infect Dis doi: 10.1086/526792 – volume: 83 start-page: 272 issue: 2 year: 2011 ident: ref33 article-title: Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test publication-title: J Med Virol doi: 10.1002/jmv.21952 – volume: 127 start-page: 940 issue: 8 year: 2003 ident: ref35 article-title: Human papillomavirus testing methods publication-title: Arch Pathol Lab Med doi: 10.5858/2003-127-940-HPTM – year: 1991 ident: ref26 – volume: 20 start-page: 1355 issue: 10 year: 2015 ident: ref32 article-title: Uptake of community-based, self-collected HPV testing vs. visual inspection with acetic acid for cervical cancer screening in Kampala, Uganda: preliminary results of a randomised controlled trial publication-title: Trop Med Int Health doi: 10.1111/tmi.12549 – volume: 24S3 start-page: S1 year: 2006 ident: ref4 article-title: Chapter 1: HPV in the etiology of human cancer publication-title: Vaccine doi: 10.1016/j.vaccine.2006.05.115 – volume: 15 start-page: 522 year: 1995 ident: ref29 article-title: Evaluation of four alternative methods for determination of absolute CD4+ lymphocyte counts. The National Heart, Lung and Blood Institute Retrovirus Epidemiology Donor Study publication-title: J. Acquir. Immune Defic. Syndr. Hum. Retrovirol doi: 10.1097/00042560-199510050-00005 – volume: 6 start-page: 8 year: 2011 ident: ref14 article-title: HPV types, HIV and invasive cervical carcinoma risk in Kampala, Uganda: a case-control study publication-title: Infectious Agents and Cancer doi: 10.1186/1750-9378-6-8 – volume: 401 start-page: 70 year: 2010 ident: ref10 article-title: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments publication-title: Virology doi: 10.1016/j.virol.2010.02.002 – volume: 32 start-page: 5087 issue: 39 year: 2014 ident: ref19 article-title: Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial publication-title: Vaccine doi: 10.1016/j.vaccine.2014.06.038 – volume: 110 start-page: 2804 issue: 11 year: 2014 ident: ref23 article-title: Introduction and sustained high coverage of the HPV Bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types publication-title: Br J Cancer doi: 10.1038/bjc.2014.198 – volume: 18 start-page: 384 issue: 4 year: 1998 ident: ref28 article-title: Optimizing the delivery of HIV counseling and testing services: the Uganda experience using rapid HIV antibody test algorithms publication-title: J Acquir Immune Defic Syndr Hum Retrovirol doi: 10.1097/00042560-199808010-00011 – volume: 123 start-page: 2180 issue: 9 year: 2008 ident: ref16 article-title: Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala, Uganda publication-title: Int J Cancer doi: 10.1002/ijc.23762 – volume: 32 start-page: 26 year: 2014 ident: ref24 article-title: Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunization in England publication-title: Vaccine doi: 10.1016/j.vaccine.2013.10.085 – volume: 95 start-page: 4 40 issue: 13 year: 1983 ident: ref30 article-title: Recent progress in syphilis serology publication-title: Wien Klin Wochenschr – volume: 5 start-page: 7 year: 2010 ident: ref36 article-title: Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda publication-title: Infect Agent Cancer doi: 10.1186/1750-9378-5-7 – volume: 24 start-page: 576 issue: 3 year: 2014 ident: ref31 article-title: A multicountry evaluation of careHPV testing, visual inspection with acetic acid, and papanicolaou testing for the detection of cervical cancer publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0000000000000084 – volume: 89 start-page: 821 year: 2011 ident: ref17 article-title: Human papillomavirus vaccine delivery strategies that achieved high coverage in low-and middle income countries publication-title: Bull World Health Organ doi: 10.2471/BLT.11.089862 – year: 2012 ident: ref7 article-title: Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 100B: A Review of Human Carcinogens: Biological Agents – volume: 131 start-page: 2832 year: 2013 ident: ref20 article-title: Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination publication-title: Int. J. Cancer doi: 10.1002/ijc.27586 – volume: 189 start-page: 12 issue: 1 year: 1999 ident: ref3 article-title: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide publication-title: J Pathol doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F – volume: 135 start-page: 432 issue: 2 year: 2014 ident: ref2 article-title: Trends in the incidence of cancer in Kampala, Uganda 1991–2010 publication-title: Int J Cancer doi: 10.1002/ijc.28661 – reference: 8548331 - J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 15;10(5):522-30 – reference: 21181922 - J Med Virol. 2011 Feb;83(2):272-6 – reference: 22084528 - Bull World Health Organ. 2011 Nov 1;89(11):821-830B – reference: 18711697 - Int J Cancer. 2008 Nov 1;123(9):2180-7 – reference: 18237268 - J Infect Dis. 2008 Feb 15;197(4):555-62 – reference: 19586656 - Lancet. 2009 Jul 25;374(9686):301-14 – reference: 21749691 - Infect Agent Cancer. 2011 Jul 12;6(1):11 – reference: 24211166 - Vaccine. 2013 Dec 17;32(1):26-32 – reference: 16949995 - Vaccine. 2006 Aug 31;24 Suppl 3:S3/1-10 – reference: 20380709 - Infect Agent Cancer. 2010 Apr 09;5:7 – reference: 23301385 - Anal Quant Cytopathol Histpathol. 2012 Oct;34(5):257-63 – reference: 6356627 - Wien Klin Wochenschr. 1983 Jun 24;95(13):440-3 – reference: 24736582 - Br J Cancer. 2014 May 27;110(11):2804-11 – reference: 18577214 - BMC Infect Dis. 2008 Jun 24;8:85 – reference: 20206957 - Virology. 2010 May 25;401(1):70-9 – reference: 8594834 - World Health Organ Tech Rep Ser. 1995;854:1-452 – reference: 9704945 - J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 1;18(4):384-8 – reference: 25018097 - Vaccine. 2014 Sep 3;32(39):5087-97 – reference: 24557438 - Int J Gynecol Cancer. 2014 Mar;24(3):576-85 – reference: 16331617 - Int J Cancer. 2006 Mar 1;118(5):1071-6 – reference: 23928291 - Virology. 2013 Oct;445(1-2):224-31 – reference: 24615279 - Int J Cancer. 2014 Jul 15;135(2):432-9 – reference: 12873165 - Arch Pathol Lab Med. 2003 Aug;127(8):940-5 – reference: 10451482 - J Pathol. 1999 Sep;189(1):12-9 – reference: 12571259 - N Engl J Med. 2003 Feb 6;348(6):518-27 – reference: 21226933 - BMC Infect Dis. 2011 Jan 12;11:13 – reference: 24552260 - BMC Infect Dis. 2014 Feb 19;14:87 – reference: 26031572 - Trop Med Int Health. 2015 Oct;20(10):1355-67 – reference: 21702999 - Infect Agent Cancer. 2011 Jun 25;6(1):8 – reference: 19486508 - Infect Agent Cancer. 2009 Jun 01;4:8 – reference: 22492244 - Int J Cancer. 2012 Dec 15;131(12):2832-8 |
| SSID | ssj0053866 |
| Score | 2.259929 |
| Snippet | The objective of this study was to determine the prevalence and some predictors for vaccine and non-vaccine types of HPV infections among bivalent HPV... |
| SourceID | plos doaj swepub pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0160099 |
| SubjectTerms | Adolescent Biology and Life Sciences Body mass Care and treatment Causes of CD4 antigen CD8 antigen Clinical Laboratory Medicine Clinical Medicine Coinfection Comparative analysis Cross-Sectional Studies Female Genetic aspects Genotype Genotyping Girls Health aspects Health risks Health Sciences HIV Infections - epidemiology HIV Infections - microbiology Human immunodeficiency virus Human papillomavirus Human papillomavirus 16 Human papillomavirus 16 - drug effects Human papillomavirus 16 - genetics Human papillomavirus 16 - immunology Human papillomavirus 18 - drug effects Human papillomavirus 18 - genetics Human papillomavirus 18 - immunology Humans Hälsovetenskap Immunization Immunization Programs - organization & administration Infections Klinisk laboratoriemedicin Klinisk medicin Lentivirus Lymphocytes Mass Vaccination Medical and Health Sciences Medicin och hälsovetenskap Medicine and Health Sciences Papillomaviridae Papillomavirus infections Papillomavirus Infections - epidemiology Papillomavirus Infections - immunology Papillomavirus Infections - prevention & control Papillomavirus Vaccines - administration & dosage People and Places Pilot Projects Prevalence Retroviridae Risk analysis Risk factors Sexual partners Sexually transmitted diseases STD Strains (organisms) Syphilis Syphilis - epidemiology Syphilis - microbiology Treponema pallidum Uganda - epidemiology Urban areas Vaccination Vaccines Womens health Young Adult |
| SummonAdditionalLinks | – databaseName: Advanced Technologies & Aerospace Database dbid: P5Z link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbhMxELagcOAClL8GChjET3vY1vvr9Qm1haqVUIlaGpVeLK-zTldEuyGbIHgpHoJX4IWY8TppV0QFiUsOO2Nv1p4Ze8bjbwh5gbuClEfGEyo1XqQ06JziyouigIVZmke5hS_uvecHB-nJiei6gFvt0ipnNtEa6n6lMUa-6acMS0LAbvnN6IuHVaPwdNWV0LhKriFKAipmNz6dWWLQ5SRx1-VC7m-62dkYVWW-gchqzCK-ni9HFrV_bpuXRsOqXrTx_DN_soUyalem3Vv_-023yU23J6VbjRAtkyt5eYcsO62v6ZqDpl6_S34dFYMSk4tgPobf6SHivuZ9CgxYTAWEFlvQytCe0nhi76GbS_e6Pc9P4H_QfZf6VdbUVjlyfLDf7dMdlw1PJxU9qErvAsmaJGqLbdJ4I6afQD2hByxvThXdLuyLJxfe415P13Yw5jwuvv38sU67xbCa0G4TeqJFSY8HGEa5R453333c2fNcWQhPp4JNPCOM6ptUJbEyfZb1mc6ZynXEQ1hEojQKAxNok4lUJMYYrkwWZTDG4FcB2e_r8D5ZKkEEVgjVWcqSzI8yBj_geWY84SrJRS6YCn3jd0g4kw6pHWY6lu4YSnsQyMF3aqZIokxJJ1Md4s1bjRrMkL_wb6PgzXkR8ds-qMYD6QyIzAIdaT9UWc79SPE0y_KAJUaIOA20iqGTpyi2srk-O7dbcitChEFf8LRDnlsORP0oMa1ooKZ1Lfc_9P6B6eiwxfTaMZkKhkMrd5UDvgnRxFqcqy1OsF26RV5BJZuNSi3PNQJaznRmMfnZnIydYqpgmVdTyyPAT-GhfxkP-NVpAotXhzxodHk--gFHZFwWdwhvaXlretqUsjizwOyR4OCAQZ8vG3vQavK26G3ZGa3GUxljnYoOOV3A17jd0mF9ncnhVNa5HF0I4ksl_EwLxqXwhS8xBCPTJOAyMaAhOQuBHnbIqwWdu0efC-wzZmHEwoeXD_QjcgN8hMTmvAarZGkynuaPyXX9dVLU4yfW3v4GFqXlcQ priority: 102 providerName: ProQuest – databaseName: Public Library of Science dbid: FPL link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NbtQwELagcOAClL8GChjET3tIGydObB_bQtVKVVm1dFW4WI7XbiNWyWqzi-CleAhegRdinHiXBpa_Sw6Zz45iz4w9zuQbhJ65XQFn1IZCcRtSpcHmFFMhpXGU5NxQ09AX9w_Y4SE_PRW9H4HiT1_wE0Y2_ZhujKrSbDg-NNjTXEZX4iTLXArXbu9g5nnBdrPM_x73u5ad5adh6Z_74qXRsKoXbTR_zZfssIo2K9Hujf99h5vout9z4q1WSZbRJVPeQsveqmu85qmn12-jb8fFWemSh2C8h5_xkeN1NQMMAFcsBZTStcCVxX2l3Rf50IWxeK_XD0m2STje96ldZY2bKkYeB_vZAd7x2e54UuHDqgwviBqXg5timjjdSPE7MD_owZUvxwpvF82DJxee4x-P13bcmfK4-PT1yzruFcNqgnvt0RIuSnxy5o5J7qCT3ddvd_ZCX_Yh1FxEk9AKqwaWqyxVdhDlg0ibSBlNWQKLBOU0iW2sbS64yKy1TNmc5qBaEDeBmAx0chctlTDQKwjrnEdZTmgewQUiy5xlTGVGGBGphFgSoGSmDVJ7TnRXmmMomw99DGKjdoqkmznpZy5A4bzVqOUE-Qt-2ynaHOsYvZsboCLSOwiZx5pqkqjcMEIV43lu4iizQqQ81iqFTh47NZXt77FzvyS3qGMQJILxAD1tEI7Vo3RpQ2dqWtdy_03_H0DHRx3QSw-yFQyHVv5XDXgnxxbWQa52kOCbdEe84oxqNiq1JDxyhV0g5oWWM0NbLH4yF7tOXSpgaappgxEQh7CE_AkDcTPPYHEK0L3WduejHzPHfBulAWIdq-5MT1dSFucN8ToVDAIs6PN5a_-dJq-K_lYzo9V4KlNXhyJA7xfg2rBaei6vczmcytrI0YVDeqkEybWImBREEOmOWCTPYiYzCxZiogTkSYBeLOjc3_pQuD7TKKFRcv_3c_AAXYP9f9bks8araGkynpqH6Kr-OCnq8aPGt34H6LnTrw priority: 102 providerName: Public Library of Science |
| Title | Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27482705 https://www.proquest.com/docview/1808344428 https://www.proquest.com/docview/1809045731 https://www.proquest.com/docview/1811886488 https://pubmed.ncbi.nlm.nih.gov/PMC4970808 https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-51618 http://kipublications.ki.se/Default.aspx?queryparsed=id:134072786 https://doaj.org/article/b2c4c13abe714a78bbe206f99582ca59 http://dx.doi.org/10.1371/journal.pone.0160099 |
| Volume | 11 |
| WOSCitedRecordID | wos000381110700023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Advanced Technologies & Aerospace Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: P5Z dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: Agricultural Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M0K dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/agriculturejournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7P dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Engineering Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7S dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PATMY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: Health Medical collection customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7X7 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Materials Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KB. dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/materialsscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7RV dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: BENPR dateStart: 20061201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8C1 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PIMPY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVATS databaseName: Public Library of Science (PLoS) Journals Open Access customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: FPL dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.plos.org/publications/ providerName: Public Library of Science |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagcOCCKK8GSjGIR3vI1nnaOXaXVq3aLlFLV20vluON24hVstoHgj_Fj-Av8IcYO95lI1aUA5c5ZMaOYs-MPc74G4Te6F0Bo6FyE8GUGwoJNieocMPQJ0HG8jA38MW9I9rtsvPzJF0o9aVzwmp44HrgtjNfhtILRJZTLxSUZVnuk1glScR8KSJzdQ92PbNgqvbBYMVxbC_KBdTbtvPSGlZl3tKYasRgvf5eiAxe_9wrrwwH1XjZlvPPzMkGvqhZk_YeoPt2M4l36o9YRbfy8iFateY6xpsWU3rrEfp5WlyVOisIBnLwDZ9owNa8j0FAV0EBbdMtcKVwT0j9q93V8SneT3uuF297DB_YnK1yjE15IisHG9U-7tg0djypcLcq3QWW8SXYVMnEUSvCF2BX0IOuS44FbhfmxZOF99jX482OPiweFV9_fN_CaTGoJjitz4xwUeKzK33-8Rid7e1-6uy7tp6DK1lCJq5KlOgrJuJIqD7J-kTmROQypAF4_5CFga98qbKEJbFSigqVhRnoDAREwPb6MniCVkqYwTWEZcZInHlhRoBAyJjRmIo4T_KEiMBTnoOC2eRyacHOdc2NATd_8CgEPfUUca0S3KqEg9x5q2EN9nGDfFvrzVxWQ3WbB6DA3Cowv0mBHfRSax2v773OHQ7fCTU0oAdRvoNeGwkN11HqfKArMR2P-cHH3j8InZ40hN5bIVXBcEhh72DAN2kYsIbkekMSnI5ssNe0jcxGZcw9RnTFFghmoeXMbpazX83ZulOd41fm1dTIJBBg0MD7mwwExCyGVcdBT2tTnI--TzWkLYkcRBtG2pieJqcsrg2iephQ8CHQ59vanBtNPhS9HTOj1WjKI11gwkGXS-TqeJlbkK5rPpjycc6HC6fvXCReJhNCeeIlHtdnJ5zFPuWxAgvJSQD8wEHvlnRuH30udJ8RCUISPPsf2vcc3YMQIDYprf46WpmMpvkLdFd-mRTj0Qa6TU96mp5TQxlQ1vE20J32bjc92TBOF-heegT0sN0CekwONaWpoadA0-gSWqQHx-nFLwN75FU |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lc9MwENaUwgxcgPJqoFDBUGgPbv2KZR8Ypg86zbSETB-ZwkXIipV6yNghToD-qf4I_gJ_iF1ZSeshU7j0wMUHayWNpd1PWnn1LSEvcVcQMl9ZkQiV5QsJNieYsHzftb04TPxE0xe391izGR4fR60Zcja-C4NhlWNM1EDdySWeka85oY0pIWC3_Lb_1cKsUfh3dZxCo1SL3eT0O7hsxZvGFszvkutuvzvc3LFMVgFLhpE9tFSkREeFIqgL1bHjji0TWyTSZx5gkB_6nqtcqeIojAKlFBMq9mPoFrblUOx0pAftXiPXAccZhpCx44mDB9gRBOZ6nsecNaMNq_08S1aRyc3WDLPny5_OEjBZC2b7vbyYttH9M16zwmqqV8LtO__bGN4lt82em66XRjJHZpLsHpkzqFbQZUO9vXKf_DpIuxkGT4G-9U7pPvLaJh0KApgsBowSa9Bc0baQGJFgoRtPd1ptywngu2nDhLZlBdVZnIwc7Oc7dNNE-9NhTpt5Zl0o0pBLdTJRWl-t048wRtACpm-ngm6kuuPhhX5M93R5E8_UB-mPn2crtJX28iFtlUdrNM3oURePiR6QoysZ3IdkNgOVmydUxqEdxI4f2_AAzzpmARNBEiWRLTxHOTXijbWRS8MJj6lJelz_6GTgG5ZTxFGHudHhGrEmtfolJ8pf5DdQ0SeyyGiuX-SDLjcAyWNX-tLxRJwwxxcsjOPEtQMVRfXQlaIOjSyimfDyevAEl_m6jwyKDhhjjbzQEshqkmHYVFeMioI3PrT_QehgvyL02gipHIZDCnNVBb4J2dIqkgsVScBmWSmeR6Mej0rBzy0Qao5tdHrx80kxNoqhkFmSj7RMBH4Y85zLZBwnDANYnGvkUYkdk9F3GTL_2vUaYRVUqUxPtSRLTzTxvB8xcDChzaUSfypVttL2up7RfDDidczDUSOfpsiVxwrccJmd8N6IFwnvX_hJwUXkxDKyGY-cyOF4xMTDwGU8UGAhie1BuVcjr6Y0bl59SbHNuu35tvf48oFeJDd3Dt_v8b1Gc_cJuQX-UKDje90FMjscjJKn5Ib8NkyLwTON9ZR8vmpg_A0juke_ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxELZKQYgLb2h41SAe5bDtvr0-INQHVStQiSiNoBfjdeyyItoN2QTon-IHcOQv8IeY8TqhK6rChQOXHOKxNxnPfPZ4x98Qch93BRmLjcdlZrxYKvA5yaQXx6Ef5ZmOtaUv7r1gOzvZmze8O0e-Te_CYFrlFBMtUPcrhWfkK0HmY0kI2C2vGJcW0d3YfDr86GEFKXzTOi2n0ZjIc334GcK3-sn2Bsz1gzDcfPZ6fctzFQY8lXF_7BluZN9kMk2k6ft531fal1rFLAI8irM4Ck2oTM4znhpjmDR5nMNPgC06NAd9FcG4p8hpBjEmBn7dZH-6CgCOpKm7qhexYMVZxvKwKvUysrr5lm3211JoKwbM1oX54aCqj9v0_p672WI4tavi5oX_WZ8XyXm3F6erjfNcInO6vEwuObSr6ZKj5H58hfzYLQ5KTKoCOxwc0lfId6v7FASwiAw4K_aglaE9qTBTwcPwnm51e16Qgg7otkt5K2tqqzs5Odjn9-m6uwVAxxXdqUrvSJOFYmqLjNJkOaFvQUcwApZ1p5KuFfbB4yPPcY-nS-t41j4qvnz_-ph2i0E1pt3myI0WJd07wOOjq2Tvnyj3GpkvwfwWCFV55qd5EOc-fEDEnbOUyVRzzX0ZBSbokGhqmUI5rngsWTIQ9gUog5ixmSKB9iycPXeIN-s1bLhS_iC_hkY_k0Wmc_tFNToQDjhFHqpYBZHMNQtiybI816GfGs6TLFQygUEW0WVEc214htdiNUZmxYCzrEPuWQlkOynRzg_kpK7F9sveXwjtvmoJPXJCpgJ1KOmusMB_Qha1luStliRgtmo1L6CDT7VSi1_eCD2n_np8891ZMw6KKZKlriZWhkN8xqLgJJkgyLIUFu0Oud7gyEz7IUNGYD_pENZCmNb0tFvK4r0lpI85g8ATxnzQYFGry0bRW7UzWo0mIsH6HB2yf4xcc9wgHMfZezGYiFqL4ZGXF0LyIFfcZ4IHPBB49CSyNGQiNeAh2o-gPeqQh8cM7r76UOCYiR_FfnTjZEUvkrOAh-LF9s7zm-QchEmpTfsNb5H58Wiib5Mz6tO4qEd3LOxT8u5f4-JPvEdQsg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Significantly+Reduced+Genoprevalence+of+Vaccine-Type+HPV-16%2F18+Infections+among+Vaccinated+Compared+to+Non-Vaccinated+Young+Women+5.5+Years+after+a+Bivalent+HPV-16%2F18+Vaccine+%28Cervarix%C2%AE%29+Pilot+Project+in+Uganda&rft.jtitle=PloS+one&rft.au=Edward+Kumakech&rft.au=Vanja+Berggren&rft.au=Henry+Wabinga&rft.au=Gabriella+Lillsunde-Larsson&rft.date=2016-08-02&rft.pub=Public+Library+of+Science+%28PLoS%29&rft.eissn=1932-6203&rft.volume=11&rft.issue=8&rft.spage=e0160099&rft_id=info:doi/10.1371%2Fjournal.pone.0160099&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_b2c4c13abe714a78bbe206f99582ca59 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |